HYPD:NASDAQHyperion DeFi, Inc. Analysis
Data as of 2026-06-13 - not real-time
$2.72
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Hyperion DeFi, Inc. (HYPD) is trading at $2.72, well below its 20‑day SMA of 3.33 and the 50‑day SMA of 3.62, indicating short‑term bearish pressure. The 30‑day volatility exceeds 118% and a beta of 3.45 underscores extreme price swings relative to the market. RSI sits at 37, flirting with oversold territory, while the MACD histogram remains negative, confirming a bearish momentum. The stock is hovering just above the identified support level of 2.49 and faces resistance near 4.09, limiting upside in the near term. Volume trends are stable but modest, and the max drawdown of -84% highlights historical vulnerability. Collectively, the technical picture is cautious, with significant downside risk if the price breaches support.
On the fundamentals side, HYPD reported a record $8.8 M net income and $19.5 M adjusted EBITDA, reversing previous losses and reflecting a 119% surge in adjusted gross profit since Q3. Revenue grew about 16% year‑over‑year, yet operating margins remain deeply negative (‑20.6%) and cash flow is still out of balance, with operating cash flow at a negative $14.5 M. The balance sheet shows a high debt‑to‑equity ratio of 15.5 and a price‑to‑book of 0.53, suggesting the stock is materially undervalued relative to its book value. Management raised full‑year guidance and aims for cash‑flow breakeven by year‑end, supporting a target price of $5.65. While the upside potential is attractive, the combination of high volatility, leverage, and regulatory exposure in both biotech and DeFi sectors warrants a measured approach.
On the fundamentals side, HYPD reported a record $8.8 M net income and $19.5 M adjusted EBITDA, reversing previous losses and reflecting a 119% surge in adjusted gross profit since Q3. Revenue grew about 16% year‑over‑year, yet operating margins remain deeply negative (‑20.6%) and cash flow is still out of balance, with operating cash flow at a negative $14.5 M. The balance sheet shows a high debt‑to‑equity ratio of 15.5 and a price‑to‑book of 0.53, suggesting the stock is materially undervalued relative to its book value. Management raised full‑year guidance and aims for cash‑flow breakeven by year‑end, supporting a target price of $5.65. While the upside potential is attractive, the combination of high volatility, leverage, and regulatory exposure in both biotech and DeFi sectors warrants a measured approach.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish technical indicators (price below SMA, negative MACD)
- Proximity to support level limiting downside
- High short‑term volatility and beta
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Raised full‑year guidance and path to cash‑flow breakeven
- Undervalued price‑to‑book ratio and target upside to $5.65
- Strong recent earnings momentum and token‑monetization growth
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Strategic treasury of HYPE and related tokens offering long‑term upside
- Blend of biotech innovation and DeFi exposure creating unique growth tailwinds
- Current market price significantly below intrinsic valuation metrics
Key Metrics & Analysis
Financial Health
Revenue Growth1559.50%
ROE-135.26%
ROA-33.84%
Debt/Equity15.51
P/B Ratio0.5
Op. Cash Flow$-14523980
Free Cash Flow$-7539178
Industry P/E24.8
Technical Analysis
TrendBearish
RSI37.0
Support$2.49
Resistance$4.09
MA 20$3.33
MA 50$3.62
MA 200$4.92
MACDBearish
VolumeStable
Fear & Greed Index89.86
Valuation
Target Price$5.65
Upside/Downside107.72%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta3.45
Volatility118.20%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.